Phase II study of interleukin-2 in combination with zoledronic acid in patients with untreated metastatic renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2013
At a glance
- Drugs Interleukin-2 (Primary) ; Zoledronic acid (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Mar 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.